title: Phototherapy of mycosis fungoides.
abstract: OBJECTIVE
  Among the primary cutaneous T-cell lymphomas, mycosis fungoides (MF) is the most common disease entity. Recently, an improved understanding of the pathology, clinical presentation, and prognosis of MF has lead to the development of new and practically useful classification and staging systems. In most patients, MF presents with patches and plaques and remains confined to the skin for years and decades, making it an ideal target for phototherapy. However, treatment schedules vary widely and this review describes the current knowledge about phototherapy of MF focusing mainly on narrow- and broadband UVB and 8-methoxypsoralen plus UVA, its indications, practical aspects, and clinical outcome.
  
  
  METHODS
  Review and summary of the pertinent literature.
  
  
  CONCLUSIONS
  Since 1976, when the first report on phototherapy for MF was published, sufficient evidence has accumulated to make narrowband UVB and PUVA safe and effective treatment options for early stages of the disease. In refractory cases or more advanced stages, combination of phototherapy with systemic treatments including mainly interferons and retinoids might be valuable. Additional research is required to further define the optimal treatment schedules and the role of maintenance.
authors.affiliation: Karl Landsteiner Institute for Dermatological Research, St. Pölten, Austria. franz.trautinger@stpoelten.lknoe.at
authors.forename: Franz
authors.initials: F
authors.lastname: Trautinger
mesh_terms: D006801:Humans; D008730:Methoxsalen / Q000627:therapeutic use*; D009182:Mycosis Fungoides / Q000188:drug therapy*; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*
chemical_list: D017319:Photosensitizing Agents; D008730:Methoxsalen